Importance: Among patients with ST-segment elevation myocardial infarction (STEMI) referred for primary percutaneous coronary intervention (PCI), a survival benefit associated with radial access compared with femoral access remains controversial. Objective: To assess whether there is a survival benefit when radial access is used instead of femoral access among patients with STEMI referred for primary PCI. Design, Setting, and Participants: This multicenter, open-label, randomized clinical trial was conducted at 5 PCI centers in Canada. In total, 2292 patients with STEMI referred for primary PCI were enrolled between July 2011 and December 2018, with a 30-day follow-up. The primary analyses were conducted based on the intention-to-treat population. Interventions: Patients were randomized to radial access (n = 1136) or to femoral access (n = 1156) for PCI. Main Outcomes and Measures: Initially, the primary outcome was bleeding, but this outcome was modified to 30-day all-cause mortality following the recommendation of the granting agency. Secondary outcomes included recurrent myocardial infarction, stroke, and Thrombolysis in Myocardial Infarction-defined major or minor bleeding. Results: Among the 2292 patients enrolled, the mean (SD) age of the patients randomized to radial access was 61.6 (12.3) years and to femoral access was 62.0 (12.1) years, with 883 male patients in the radial access and 901 male patients in the femoral access group. The trial was stopped early following a futility analysis. Primary PCI was performed in 1082 of 1136 patients (95.2%) in the radial access group and 1109 of 1156 patients (95.9%) in the femoral access group. Bivalirudin was administered to 1001 patients (88.1%) in the radial access group and to 1068 patients (92.4%) in the femoral access group, whereas glycoprotein IIb/IIIa inhibitors were administered in only 69 patients (6.1%) in the radial access group and 68 patients (5.9%) in the femoral access group. A vascular closure device was used in 789 patients (68.3%) in the femoral group. The primary outcome, 30-day all-cause mortality, occurred in 17 patients (1.5%) assigned to radial access and in 15 patients (1.3%) assigned to femoral access (relative risk [RR], 1.15; 95% CI, 0.58-2.30; P = .69). There were no significant differences between patients assigned to radial and femoral access in the rates of reinfarction (1.8% vs 1.6%; RR, 1.07; 95% CI, 0.57-2.00; P = .83), stroke (1.0% vs 0.4%; RR, 2.24; 95% CI, 0.78-6.42; P = .12), and bleeding (1.4% vs 2.0%; RR, 0.71; 95% CI, 0.38-1.33; P = .28). Conclusions and Relevance: No significant differences were found for survival or other clinical end points at 30 days after the use of radial access vs femoral access in patients with STEMI referred for primary PCI. However, small absolute differences in end points cannot be definitively refuted given the premature termination of the trial. Trial Registration: ClinicalTrials.gov identifier: NCT01398254.
Importance: Among patients with ST-segment elevation myocardial infarction (STEMI) referred for primary percutaneous coronary intervention (PCI), a survival benefit associated with radial access compared with femoral access remains controversial. Objective: To assess whether there is a survival benefit when radial access is used instead of femoral access among patients with STEMI referred for primary PCI. Design, Setting, and Participants: This multicenter, open-label, randomized clinical trial was conducted at 5 PCI centers in Canada. In total, 2292 patients with STEMI referred for primary PCI were enrolled between July 2011 and December 2018, with a 30-day follow-up. The primary analyses were conducted based on the intention-to-treat population. Interventions: Patients were randomized to radial access (n = 1136) or to femoral access (n = 1156) for PCI. Main Outcomes and Measures: Initially, the primary outcome was bleeding, but this outcome was modified to 30-day all-cause mortality following the recommendation of the granting agency. Secondary outcomes included recurrent myocardial infarction, stroke, and Thrombolysis in Myocardial Infarction-defined major or minor bleeding. Results: Among the 2292 patients enrolled, the mean (SD) age of the patients randomized to radial access was 61.6 (12.3) years and to femoral access was 62.0 (12.1) years, with 883 male patients in the radial access and 901 male patients in the femoral access group. The trial was stopped early following a futility analysis. Primary PCI was performed in 1082 of 1136 patients (95.2%) in the radial access group and 1109 of 1156 patients (95.9%) in the femoral access group. Bivalirudin was administered to 1001 patients (88.1%) in the radial access group and to 1068 patients (92.4%) in the femoral access group, whereas glycoprotein IIb/IIIa inhibitors were administered in only 69 patients (6.1%) in the radial access group and 68 patients (5.9%) in the femoral access group. A vascular closure device was used in 789 patients (68.3%) in the femoral group. The primary outcome, 30-day all-cause mortality, occurred in 17 patients (1.5%) assigned to radial access and in 15 patients (1.3%) assigned to femoral access (relative risk [RR], 1.15; 95% CI, 0.58-2.30; P = .69). There were no significant differences between patients assigned to radial and femoral access in the rates of reinfarction (1.8% vs 1.6%; RR, 1.07; 95% CI, 0.57-2.00; P = .83), stroke (1.0% vs 0.4%; RR, 2.24; 95% CI, 0.78-6.42; P = .12), and bleeding (1.4% vs 2.0%; RR, 0.71; 95% CI, 0.38-1.33; P = .28). Conclusions and Relevance: No significant differences were found for survival or other clinical end points at 30 days after the use of radial access vs femoral access in patients with STEMI referred for primary PCI. However, small absolute differences in end points cannot be definitively refuted given the premature termination of the trial. Trial Registration: ClinicalTrials.gov identifier: NCT01398254.
Authors: Laura Mauri; Wen-hua Hsieh; Joseph M Massaro; Kalon K L Ho; Ralph D'Agostino; Donald E Cutlip Journal: N Engl J Med Date: 2007-02-12 Impact factor: 91.245
Authors: Vasim Farooq; Dick Goedhart; Peter Ludman; Mark A de Belder; Alun Harcombe; Magdi El-Omar Journal: Circ Cardiovasc Interv Date: 2016-06 Impact factor: 6.546
Authors: Gregg W Stone; Bernhard Witzenbichler; Giulio Guagliumi; Jan Z Peruga; Bruce R Brodie; Dariusz Dudek; Ran Kornowski; Franz Hartmann; Bernard J Gersh; Stuart J Pocock; George Dangas; S Chiu Wong; Martin Fahy; Helen Parise; Roxana Mehran Journal: Lancet Date: 2011-06-12 Impact factor: 79.321
Authors: Marco Valgimigli; Andrea Gagnor; Paolo Calabró; Enrico Frigoli; Sergio Leonardi; Tiziana Zaro; Paolo Rubartelli; Carlo Briguori; Giuseppe Andò; Alessandra Repetto; Ugo Limbruno; Bernardo Cortese; Paolo Sganzerla; Alessandro Lupi; Mario Galli; Salvatore Colangelo; Salvatore Ierna; Arturo Ausiello; Patrizia Presbitero; Gennaro Sardella; Ferdinando Varbella; Giovanni Esposito; Andrea Santarelli; Simone Tresoldi; Marco Nazzaro; Antonio Zingarelli; Nicoletta de Cesare; Stefano Rigattieri; Paolo Tosi; Cataldo Palmieri; Salvatore Brugaletta; Sunil V Rao; Dik Heg; Martina Rothenbühler; Pascal Vranckx; Peter Jüni Journal: Lancet Date: 2015-03-16 Impact factor: 79.321
Authors: Philippe Gabriel Steg; Stefan James; Robert A Harrington; Diego Ardissino; Richard C Becker; Christopher P Cannon; Håkan Emanuelsson; Ariel Finkelstein; Steen Husted; Hugo Katus; Jan Kilhamn; Sylvia Olofsson; Robert F Storey; W Douglas Weaver; Lars Wallentin Journal: Circulation Date: 2010-11-08 Impact factor: 29.690
Authors: Ivo Bernat; David Horak; Josef Stasek; Martin Mates; Jan Pesek; Petr Ostadal; Vlado Hrabos; Jaroslav Dusek; Jiri Koza; Zdenek Sembera; Miroslav Brtko; Ondrej Aschermann; Michal Smid; Pavel Polansky; Abdul Al Mawiri; Jan Vojacek; Josef Bis; Olivier Costerousse; Olivier F Bertrand; Richard Rokyta Journal: J Am Coll Cardiol Date: 2013-11-21 Impact factor: 24.094
Authors: Marco Valgimigli; Enrico Frigoli; Sergio Leonardi; Martina Rothenbühler; Andrea Gagnor; Paolo Calabrò; Stefano Garducci; Paolo Rubartelli; Carlo Briguori; Giuseppe Andò; Alessandra Repetto; Ugo Limbruno; Roberto Garbo; Paolo Sganzerla; Filippo Russo; Alessandro Lupi; Bernardo Cortese; Arturo Ausiello; Salvatore Ierna; Giovanni Esposito; Patrizia Presbitero; Andrea Santarelli; Gennaro Sardella; Ferdinando Varbella; Simone Tresoldi; Nicoletta de Cesare; Stefano Rigattieri; Antonio Zingarelli; Paolo Tosi; Arnoud van 't Hof; Giacomo Boccuzzi; Elmir Omerovic; Manel Sabaté; Dik Heg; Peter Jüni; Pascal Vranckx Journal: N Engl J Med Date: 2015-09-01 Impact factor: 91.245
Authors: Borja Ibanez; Stefan James; Stefan Agewall; Manuel J Antunes; Chiara Bucciarelli-Ducci; Héctor Bueno; Alida L P Caforio; Filippo Crea; John A Goudevenos; Sigrun Halvorsen; Gerhard Hindricks; Adnan Kastrati; Mattie J Lenzen; Eva Prescott; Marco Roffi; Marco Valgimigli; Christoph Varenhorst; Pascal Vranckx; Petr Widimský Journal: Eur Heart J Date: 2018-01-07 Impact factor: 29.983
Authors: Muhammad Junaid Ahsan; Soban Ahmad; Azka Latif; Noman Lateef; Mohammad Zoraiz Ahsan; Waiel Abusnina; Sandeep Nathan; S Elissa Altin; Dhaval S Kolte; John C Messenger; Mark Tannenbaum; Andrew M Goldsweig Journal: Eur Heart J Qual Care Clin Outcomes Date: 2022-09-05
Authors: Matthias Hasun; Jakob Dörler; Hannes F Alber; Axel Bauer; Rudolf Berger; Günter Christ; Matthias Frick; Uta C Hoppe; Kurt Huber; Gudrun Lamm; Elisabeth Laßnig; Dirk von Lewinski; Anna Rab; Franz X Roithinger; Herwig Schuchlenz; Peter Siostrzonek; Johann Sipötz; Thomas Stefenelli; Clemens Steinwender; Michael Edlinger; Franz Weidinger Journal: Cardiovasc Diagn Ther Date: 2021-06